In the News
Harvard Business Review: Using AI to Understand What Causes Diseases
Sema Sgaier and Francesca Domini of Surgo Foundation share how they causal AI can bring new clarity to understanding the underlying cause of disease. Read the full article here.
read more
Cigna Invests In GNS Healthcare Precision Medicine Venture
Forbes contributor Bruce Japsen notes that the Cigna investment "fits the effort by health insurance companies to use claims data and related patient health information to better target illness and provide more cost-effective and high quality patient care. These...
read more
GNS Among Ways Amgen is Applying AI to Combat Serious Illness
Wired magazine dove in to a few approaches Amgen is taking to using AI to combat serious illness and one of those ways is by partnering with GNS! Amgen, the world's largest independent biotech company, is leading the charge in combining life sciences with data and...
read more
Iya Khalil weighs in on AI in Real-World Drug Discovery
Following the recent Bio-IT conference, Iya Khalil and fellow keynote panelists weigh in on how AI is impacting real-world drug discovery efforts. Read the full article here.
read more
GNS CEO Colin Hill joins rank of Top 50 Healthcare Technology CEOs of 2019
The Healthcare Technology Report evaluates the hundreds of CEOs that lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas. They gather data on each nominee’s professional background...
read more
Adding Artificial Intelligence to Drug Discovery – Iya Khalil interviewed by GEN News
"AI is being used to really leverage learning from large-scale datasets, and those large-scale datasets are used to get to better novel targets." - Iya Khalil, GNS Co-Founder and COO, joins Mike May of Genetic Engineering & Biotechnology News to discuss AI in drug...
read more
GNS Co-founder, Iya Khalil interviewed by BioCentury: A Frequentist and a Bayesian Walk Into a Trial
GNS Co-Founder and COO Iya Khalil weighed in on the stand-off between Bayesians and frequentist. Read the full piece here.
read more
How A.I. Is Finding New Cures in Old Drugs
GNS CEO and Co-Founder Colin Hill is shares his thoughts on the stat of AI and biopharma with Fortune reporter Tiernan Ray. Read the full article here.
read more
GNS Co-Founder Iya Khalil Named to Forbes list of “50 Women-Led Startups That Are Crushing Tech”
GNS Co-Founder Iya Khalil joins 49 other female entrepreneurs who are pushing the frontiers of innovation across various industries. Read the full list here.
read more
GNS Co-Founder and CEO Colin Hill Discusses how AI will Power the Future of in silico Clinical Trials
GNS Co-Founder and CEO Colin Hill sat down with Outsourcing Pharma's Melissa Fassbender to discuss how in silico are making personalized medicine a reality. The interview covered how technology is driving pharma efforts to transition from resource-intensive trials to...
read more